ReShape Lifesciences Inc. financial data

Symbol
RSLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
1001 Calle Amanecer, San Clemente, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
OBALON THERAPEUTICS INC (to 6/21/2021)
Latest financial report
10-K - Q4 2024 - Apr 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 152 % -29.2%
Quick Ratio 77 % +13.7%
Debt-to-equity 184 % +99.1%
Return On Assets -114 % -16.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.3M shares -51.9%
Common Stock, Shares, Outstanding 730K shares +80.5%
Entity Public Float 5.64M USD +11.1%
Common Stock, Value, Issued 29K USD +867%
Weighted Average Number of Shares Outstanding, Basic 516K shares +402%
Weighted Average Number of Shares Outstanding, Diluted 516K shares +402%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.01M USD -7.74%
Research and Development Expense 1.8M USD -22.1%
General and Administrative Expense 6.93M USD -32.9%
Operating Income (Loss) -7.73M USD +49.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.09M USD +37.4%
Income Tax Expense (Benefit) 39K USD -25%
Net Income (Loss) Attributable to Parent -7.13M USD +37.4%
Earnings Per Share, Basic -13.8 USD/shares +87.5%
Earnings Per Share, Diluted -13.8 USD/shares +87.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 693K USD -84.5%
Accounts Receivable, after Allowance for Credit Loss, Current 1M USD -41.2%
Inventory, Net 2.46M USD -34.2%
Other Assets, Current 51K USD -45.7%
Assets, Current 4.59M USD -55.4%
Deferred Income Tax Assets, Net 22K USD -21.4%
Property, Plant and Equipment, Net 38K USD -36.7%
Operating Lease, Right-of-Use Asset 116K USD -53.6%
Other Assets, Noncurrent 29K USD 0%
Assets 4.79M USD -55.1%
Accounts Payable, Current 2.21M USD +30.7%
Employee-related Liabilities, Current 694K USD -1%
Accrued Liabilities, Current 1.69M USD -6.95%
Liabilities, Current 4.99M USD +32%
Operating Lease, Liability, Noncurrent 41K USD -72.8%
Liabilities 5.05M USD +26.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -104K USD -18.2%
Retained Earnings (Accumulated Deficit) -643M USD -1.12%
Stockholders' Equity Attributable to Parent -253K USD -104%
Liabilities and Equity 4.79M USD -55.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.07M USD +59.1%
Net Cash Provided by (Used in) Financing Activities 10.2M USD
Net Cash Provided by (Used in) Investing Activities -7K USD -100%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 730K shares +80.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.08M USD -141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 793K USD -82.6%
Deferred Tax Assets, Valuation Allowance 79.9M USD +3.85%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 79.9M USD +3.8%
Operating Lease, Liability 156K USD -40.5%
Depreciation 6K USD -83.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.15M USD +37.2%
Lessee, Operating Lease, Liability, to be Paid 174K USD -38.9%
Property, Plant and Equipment, Gross 150K USD 0%
Operating Lease, Liability, Current 115K USD +3.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 59K USD -48.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 115K USD +3.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 1K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18K USD -21.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD
Deferred Tax Assets, Operating Loss Carryforwards 71.9M USD +5.85%
Unrecognized Tax Benefits 1.05M USD 0%
Operating Lease, Payments 27K USD -69%
Additional Paid in Capital 643M USD +0.04%
Amortization of Intangible Assets 33K USD -98.2%
Deferred Tax Assets, Net of Valuation Allowance 57K USD -38%
Share-based Payment Arrangement, Expense 184K USD -76%